GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Why GSK (GSK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is GSK plc (GSK) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...
American Association of Individual Investors3h
Which Is a Better Investment, Corcept Therapeutics Incorporated or GSK plc Stock?
Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds?
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
Le Lézard6d
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir ...
FDA greenlights GSK’s drug for UTIs in women and girls
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus
U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...
ViiV Healthcare's APRETUDE Now Covered Under Canada's NIHB Program For HIV Prevention
ViiV Healthcare, a global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, Wednesday announced that APRETUDE ...
New York Post6d
FDA greenlights GSK’s drug for UTIs in women and girls
GSK plans to launch the drug in the US in the ... from its best-selling medicines and looming patent losses for its HIV treatments. Over half of all women will experience uncomplicated UTIs ...